Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Jeffrey S. Heier Sells 2,948 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey S. Heier sold 2,948 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the transaction, the insider now directly owns 269,059 shares in the company, valued at approximately $2,424,221.59. The trade was a 1.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ocular Therapeutix Trading Up 3.2 %

Shares of Ocular Therapeutix stock opened at $10.06 on Thursday. The firm has a market cap of $1.58 billion, a PE ratio of -7.62 and a beta of 1.26. Ocular Therapeutix, Inc. has a 1 year low of $2.16 and a 1 year high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock has a fifty day moving average price of $9.94 and a 200-day moving average price of $8.21.

Institutional Trading of Ocular Therapeutix

Large investors have recently added to or reduced their stakes in the stock. Atlas Capital Advisors LLC purchased a new position in Ocular Therapeutix in the second quarter valued at about $34,000. Amalgamated Bank raised its holdings in shares of Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,481 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,015 shares during the last quarter. Algert Global LLC bought a new position in Ocular Therapeutix during the second quarter valued at $69,000. Finally, Capital Performance Advisors LLP purchased a new stake in Ocular Therapeutix in the third quarter worth $70,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

OCUL has been the topic of a number of recent research reports. Scotiabank initiated coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 target price on the stock. Robert W. Baird lowered their price target on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, HC Wainwright lifted their price objective on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.71.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.